Zhiqiang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhiqiang Liu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Heshui Wu
Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 shared publications - Xin Jin
Department of Urology The Second Xiangya Hospital Central South University Changsha Hunan China
3 shared publications Xueyi Liang
Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications- Bo Wang
Department of Pancreatic Surgery
2 shared publications - Dan Li
Cardiovascular medicine department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
2 shared publications Gengdu Qin
Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022 China; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022 China
2 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 652, 218560
RNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer
- 5 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 652, 218560
Open AccessRNF43 deficiency activates YBX1-MYC-driven oxidative phosphorylation in pancreatic cancer
- Open Access
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis
KRAS mutations serve as key oncogenic drivers in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Despite the advancement of KRAS inhibitors, such as MRTX1133, for PDAC treatment, intrinsic and acquired resistance remain major barriers to their clinical efficacy. This study underscored the role of histone deacetylase 5 (HDAC5) loss in mediating intrinsic resistance to KRAS G12D inhibitors. Mechanistically, HDAC5 promoted c-Myc degradation by deacetylating K148, thereby facilitating NEDD4-mediated ubiquitination at this site. The loss of HDAC5 resulted in hyperacetylation of c-Myc at K148, impeding the ubiquitination and subsequent degradation process of c-Myc following deacetylation. Consequently, c-Myc stability and transcriptional activity were sustained even under KRAS/MEK/ERK pathway inhibition, reinforcing MAPK signaling and promoting cell survival despite KRAS suppression. Our data further demonstrated that pharmacological or genetic inhibition of c-Myc effectively reversed the resistance phenotype mediated by HDAC5 loss, suggesting a therapeutic strategy centered on KRAS-MYC dual-node blockade. Furthermore, the expression levels of HDAC5 and the acetylation status of c-Myc may serve as biomarkers for predicting the therapeutic response to MRTX1133. These findings provide insights into overcoming resistance to KRAS G12D inhibitors and offer potential biomarkers and combinatorial therapeutic strategies for precision treatment of PDAC.
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessHDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis
KRAS mutations serve as key oncogenic drivers in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Despite the advancement of KRAS inhibitors, such as MRTX1133, for PDAC treatment, intrinsic and acquired resistance remain major barriers to their clinical efficacy. This study underscored the role of histone deacetylase 5 (HDAC5) loss in mediating intrinsic resistance to KRAS G12D inhibitors. Mechanistically, HDAC5 promoted c-Myc degradation by deacetylating K148, thereby facilitating NEDD4-mediated ubiquitination at this site. The loss of HDAC5 resulted in hyperacetylation of c-Myc at K148, impeding the ubiquitination and subsequent degradation process of c-Myc following deacetylation. Consequently, c-Myc stability and transcriptional activity were sustained even under KRAS/MEK/ERK pathway inhibition, reinforcing MAPK signaling and promoting cell survival despite KRAS suppression. Our data further demonstrated that pharmacological or genetic inhibition of c-Myc effectively reversed the resistance phenotype mediated by HDAC5 loss, suggesting a therapeutic strategy centered on KRAS-MYC dual-node blockade. Furthermore, the expression levels of HDAC5 and the acetylation status of c-Myc may serve as biomarkers for predicting the therapeutic response to MRTX1133. These findings provide insights into overcoming resistance to KRAS G12D inhibitors and offer potential biomarkers and combinatorial therapeutic strategies for precision treatment of PDAC.
- Open Access
- 30 September 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
BAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer
Background: The vast majority of pancreatic cancers have been shown to be insensitive to single-agent immunotherapy. Exploring the mechanisms of immune resistance and implementing combination therapeutic strategies are crucial for PDAC patients to derive benefits from immunotherapy. Deletion of BAP1 occurs in approximately 27% of PDAC patients and is significantly correlated with poor prognosis, but the mechanism how BAP1-deletion compromises survival of patients with PDAC remain a puzzle. Methods: Bap1 knock-out KPC (KrasG12D/+; LSLTrp53R172H/+; Pdx-1-Cre) mice and control KPC mice, syngeneic xenograft models were applied to analysis the correlation between BAP1 and immune therapy response in PDAC. Immunoprecipitation, RT-qPCR, luciferase and transcriptome analysis were combined to revealing potential mechanisms. Syngeneic xenograft models and flow cytometry were constructed to examine the efficacy of the inhibitor of SIRT1 and its synergistic effect with anti-PD-1 therapy. Result: The deletion of BAP1 contributes to the resistance to immunotherapy in PDAC, which is attributable to BAP1’s suppression of the transcriptional activity of HSF1. Specifically, BAP1 competes with SIRT1 for binding to the K80 acetylated HSF1. The BAP1-HSF1 interaction preserves the acetylation of HSF1-K80 and promotes HSF1-HSP70 interaction, facilitating HSF1 oligomerization and detachment from the chromatin. Furthermore, we demonstrate that the targeted inhibition of SIRT1 reverses the immune insensitivity in BAP1 deficient PDAC mouse model. Conclusion: Our study elucidates an unrevealed mechanism by which BAP1 regulates immune therapy response in PDAC via HSF1 inhibition, and providing promising therapeutic strategies to address immune insensitivity in BAP1-deficient PDAC.
- 30 September 2024
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Open AccessBAP1 regulates HSF1 activity and cancer immunity in pancreatic cancer
Background: The vast majority of pancreatic cancers have been shown to be insensitive to single-agent immunotherapy. Exploring the mechanisms of immune resistance and implementing combination therapeutic strategies are crucial for PDAC patients to derive benefits from immunotherapy. Deletion of BAP1 occurs in approximately 27% of PDAC patients and is significantly correlated with poor prognosis, but the mechanism how BAP1-deletion compromises survival of patients with PDAC remain a puzzle. Methods: Bap1 knock-out KPC (KrasG12D/+; LSLTrp53R172H/+; Pdx-1-Cre) mice and control KPC mice, syngeneic xenograft models were applied to analysis the correlation between BAP1 and immune therapy response in PDAC. Immunoprecipitation, RT-qPCR, luciferase and transcriptome analysis were combined to revealing potential mechanisms. Syngeneic xenograft models and flow cytometry were constructed to examine the efficacy of the inhibitor of SIRT1 and its synergistic effect with anti-PD-1 therapy. Result: The deletion of BAP1 contributes to the resistance to immunotherapy in PDAC, which is attributable to BAP1’s suppression of the transcriptional activity of HSF1. Specifically, BAP1 competes with SIRT1 for binding to the K80 acetylated HSF1. The BAP1-HSF1 interaction preserves the acetylation of HSF1-K80 and promotes HSF1-HSP70 interaction, facilitating HSF1 oligomerization and detachment from the chromatin. Furthermore, we demonstrate that the targeted inhibition of SIRT1 reverses the immune insensitivity in BAP1 deficient PDAC mouse model. Conclusion: Our study elucidates an unrevealed mechanism by which BAP1 regulates immune therapy response in PDAC via HSF1 inhibition, and providing promising therapeutic strategies to address immune insensitivity in BAP1-deficient PDAC.
- Open Access
- 25 October 2021
- Published by Springer Nature in Research Square
Clinicopathological Characteristics and Prognosis of Retroperitoneal Castleman Disease: a Study of Combined Case Series
Background: Owing to the sporadic incidence, the clinicopathological features and prognosis of retroperitoneal Castleman disease (CD) are limited. We aimed to investigate the clinicopathological characteristics and prognosis of retroperitoneal CD.Patients and methods: The retroperitoneal CDs were obtained from our center and case reports extracted from Pubmed and Cochrane library from 1975 to 2020. The baseline clinical and demographic data and survival data were analyzed.Results: A total of 110 retroperitoneal CDs were enrolled in the present study. The most common symptoms were abdominal pain (34/110, 30.9%), followed by abdominal mass (22/110, 20.0%) and weight loss (10/110, 9.1%). Most tumors are 5-10 cm in diameter (61/99, 66.7%). 103/110 (93.6%) tumors are unicentric, and hyaline vascular types (93/108, 86.1%) are the most common pathological type in retroperitoneal CD. The five-year disease-free survival (DFS) and disease-specific survival (DSS) were 96.7% and 100%, respectively. Almost all tumors can be removed surgically.Conclusions: The median diameter of retroperitoneal CD is 7.0 cm. The most common type is unicentric hyaline vascular in retroperitoneal CD. Surgical resection seems to be the most effective therapy, and the five-year DFS and DSS were 98.6% and 100%.
- 25 October 2021
- Published by Springer Nature in Research Square
Open AccessClinicopathological Characteristics and Prognosis of Retroperitoneal Castleman Disease: a Study of Combined Case Series
Background: Owing to the sporadic incidence, the clinicopathological features and prognosis of retroperitoneal Castleman disease (CD) are limited. We aimed to investigate the clinicopathological characteristics and prognosis of retroperitoneal CD.Patients and methods: The retroperitoneal CDs were obtained from our center and case reports extracted from Pubmed and Cochrane library from 1975 to 2020. The baseline clinical and demographic data and survival data were analyzed.Results: A total of 110 retroperitoneal CDs were enrolled in the present study. The most common symptoms were abdominal pain (34/110, 30.9%), followed by abdominal mass (22/110, 20.0%) and weight loss (10/110, 9.1%). Most tumors are 5-10 cm in diameter (61/99, 66.7%). 103/110 (93.6%) tumors are unicentric, and hyaline vascular types (93/108, 86.1%) are the most common pathological type in retroperitoneal CD. The five-year disease-free survival (DFS) and disease-specific survival (DSS) were 96.7% and 100%, respectively. Almost all tumors can be removed surgically.Conclusions: The median diameter of retroperitoneal CD is 7.0 cm. The most common type is unicentric hyaline vascular in retroperitoneal CD. Surgical resection seems to be the most effective therapy, and the five-year DFS and DSS were 98.6% and 100%.
- 1 October 2021
- Published by Elsevier in Cancer Letters
- Vol. 519, 277-288
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis
- 1 October 2021
- Published by Elsevier in Cancer Letters
- Vol. 519, 277-288
SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis
- Open Access
- 1 August 2021
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 68, 102559
Active drain system with reticulated open-pore foam-surface dressing for postoperative pancreatic fistula in a rat model
Background: Postoperative pancreatic fistula (POPF) is one of the most harmful complications after pancreatic resection. Efficient drainage affects the clinical outcome of POPF. Inefficient drain of the fluid collection should contribute greatly to the need of additional interventional drainage, secondary morbid complications, and death. Methods: A rat model of POPF was established by distal pancreatosplenectomy. A novel active drain system (ADS) for POPF was developed by wrapping polyvinyl alcohol sponges (PVA) to an end of the drainage tube. Passive drain system (PDS), ADS and ADS with PVA were used for POPF in rat models. The volume and amylase of ascites were measured. CT scan was applied to assess abdominal fluid collection. Rats pancreatic transection stumps were stained by hematoxylin and eosin (H&E). Results: The volume of drainage of ADS with PVA group was less than that of PDS group and ADS group at late stage. CT scan showed obvious abdominal fluid collections in 2/8, 2/8 and 0/8 rats in PDS, ADS and ADS with PVA group separately. Macrofindings showed significant intra-abdominal adhesions and inflammation in PDS and ADS group but not in ADS with PVA group. H&E staining showed less inflammatory cells and destroyed pancreatic glands in ADS with PVA group. Conclusion: ADS with PVA drained ascites effectively in the rat model of POPF. The effective drainage of pancreatic juice reduced the inflammation of abdominal organs and pancreatic resection stumps, and might promote the healing of POPF.
- 1 August 2021
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 68, 102559
Open AccessActive drain system with reticulated open-pore foam-surface dressing for postoperative pancreatic fistula in a rat model
Background: Postoperative pancreatic fistula (POPF) is one of the most harmful complications after pancreatic resection. Efficient drainage affects the clinical outcome of POPF. Inefficient drain of the fluid collection should contribute greatly to the need of additional interventional drainage, secondary morbid complications, and death. Methods: A rat model of POPF was established by distal pancreatosplenectomy. A novel active drain system (ADS) for POPF was developed by wrapping polyvinyl alcohol sponges (PVA) to an end of the drainage tube. Passive drain system (PDS), ADS and ADS with PVA were used for POPF in rat models. The volume and amylase of ascites were measured. CT scan was applied to assess abdominal fluid collection. Rats pancreatic transection stumps were stained by hematoxylin and eosin (H&E). Results: The volume of drainage of ADS with PVA group was less than that of PDS group and ADS group at late stage. CT scan showed obvious abdominal fluid collections in 2/8, 2/8 and 0/8 rats in PDS, ADS and ADS with PVA group separately. Macrofindings showed significant intra-abdominal adhesions and inflammation in PDS and ADS group but not in ADS with PVA group. H&E staining showed less inflammatory cells and destroyed pancreatic glands in ADS with PVA group. Conclusion: ADS with PVA drained ascites effectively in the rat model of POPF. The effective drainage of pancreatic juice reduced the inflammation of abdominal organs and pancreatic resection stumps, and might promote the healing of POPF.
- Open Access
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1) , 4350417
Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis
Objective. To evaluate the impacts of different metastatic patterns on the prognosis of patients with invasive intraductal papillary mucinous neoplasm (IPMN). Materials and Methods. All patients who were diagnosed with invasive IPMN in the Surveillance, Epidemiology, and End Results SEER database (2010–2015) were included in this study. They were grouped according to different metastatic patterns. Kaplan–Meier analysis and log‐rank test were used for the comparison of their survival rates. The hazard ratio (HR) with 95% confidence interval (CI) was analyzed using the Cox proportional‐hazards model. Results. A total of 2264 cases were included in this study. The most common metastatic site was the liver. The patients with the nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. As compared to the patients with isolated liver metastasis, those with isolated lung and other organ metastases showed better overall survival rates and tumor‐specific survival rates. The patients with liver, lung, multiple, and other organ metastases or of age >60 years were the independent predictors of poor prognosis. Conclusions. The patients with isolated lung and other organ metastases demonstrated better survival outcomes as compared to those with isolated liver metastasis. The patients with nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. Further studies are needed to determine a highly selected subset of patients, who might benefit from surgery or chemotherapy.
- 1 January 2021
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2021 (1) , 4350417
Open AccessPrognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis
Objective. To evaluate the impacts of different metastatic patterns on the prognosis of patients with invasive intraductal papillary mucinous neoplasm (IPMN). Materials and Methods. All patients who were diagnosed with invasive IPMN in the Surveillance, Epidemiology, and End Results SEER database (2010–2015) were included in this study. They were grouped according to different metastatic patterns. Kaplan–Meier analysis and log‐rank test were used for the comparison of their survival rates. The hazard ratio (HR) with 95% confidence interval (CI) was analyzed using the Cox proportional‐hazards model. Results. A total of 2264 cases were included in this study. The most common metastatic site was the liver. The patients with the nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. As compared to the patients with isolated liver metastasis, those with isolated lung and other organ metastases showed better overall survival rates and tumor‐specific survival rates. The patients with liver, lung, multiple, and other organ metastases or of age >60 years were the independent predictors of poor prognosis. Conclusions. The patients with isolated lung and other organ metastases demonstrated better survival outcomes as compared to those with isolated liver metastasis. The patients with nonorgan metastasis demonstrated the best survival outcomes, while those with multiple metastases showed the worst survival outcomes. Further studies are needed to determine a highly selected subset of patients, who might benefit from surgery or chemotherapy.
- Open Access
- 1 October 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (10) , 5843-5856
Lymph node ratio predicts prognosis in patients with surgically resected invasive pancreatic cystic neoplasms
Background: In current days, the prevalence of pancreatic cystic neoplasms (PCN) is on the rise. Lymph node ratio (LNR) has emerged as a promising prognostic factor in pancreatic adenocarcinoma (PDAC). However, the prognostic value of LNR in patients with invasive PCN remains unknown. Methods: We used Surveillance, Epidemiology, and End Results (SEER) database to retrieve the baseline characteristics and clinical tumor variables of patients diagnosed with PCN between 1988 and 2014. Survival analyses were performed using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify factors associated with patient prognosis. Results: A total of 10,656 PCN cases were initially identified. Based on our exclusion criteria, our analyses included data from 1246 cases, of which 479 were patients with lymph node involvement. Patients with high LNR had shorter overall survival (OS) than patients with low LNR (median OS, 13 vs. 21 months; P=0). Our univariate and multivariate analyses identified LNR (P=0) and grade (P=0.010) as independent prognostic factors in patients with invasive PCN. Conclusions: Our findings suggest that LNR is a reliable, independent prognostic factor in patients with invasive PCN, strongly associated with OS and cancer-specific survival (CSS). LNR may represent a promising prognostic factor alternative to the AJCC (the American Joint Committee on Cancer) N stage in patients with node-positive PCN.
- 1 October 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (10) , 5843-5856
Open AccessLymph node ratio predicts prognosis in patients with surgically resected invasive pancreatic cystic neoplasms
Background: In current days, the prevalence of pancreatic cystic neoplasms (PCN) is on the rise. Lymph node ratio (LNR) has emerged as a promising prognostic factor in pancreatic adenocarcinoma (PDAC). However, the prognostic value of LNR in patients with invasive PCN remains unknown. Methods: We used Surveillance, Epidemiology, and End Results (SEER) database to retrieve the baseline characteristics and clinical tumor variables of patients diagnosed with PCN between 1988 and 2014. Survival analyses were performed using the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify factors associated with patient prognosis. Results: A total of 10,656 PCN cases were initially identified. Based on our exclusion criteria, our analyses included data from 1246 cases, of which 479 were patients with lymph node involvement. Patients with high LNR had shorter overall survival (OS) than patients with low LNR (median OS, 13 vs. 21 months; P=0). Our univariate and multivariate analyses identified LNR (P=0) and grade (P=0.010) as independent prognostic factors in patients with invasive PCN. Conclusions: Our findings suggest that LNR is a reliable, independent prognostic factor in patients with invasive PCN, strongly associated with OS and cancer-specific survival (CSS). LNR may represent a promising prognostic factor alternative to the AJCC (the American Joint Committee on Cancer) N stage in patients with node-positive PCN.
- Open Access
- 9 December 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway
Background: Recent studies have reported that Integrin alpha 2 (ITGA2) plays an essential role in tumor cell proliferation, invasion, metastasis, and angiogenesis. An abnormally expressed ITGA2 correlates with unfavorable prognoses in multiple types of cancer. However, the specific mechanism of how ITGA2 contributes to tumorigenesis remains unclear.Methods: The GEPIA web tool was used to find the clinical relevance of ITGA2 in cancer, and this significance was verified using Western blotting analysis of paired patient tissues and immunohistochemistry of the pancreatic cancer tissue. Functional assays, such as the MTS assay, colony formation assay, and transwell assay, were used to determine the biological role of ITGA2 in human cancer. The relationship between ITGA2 and programmed death-ligand 1 (PD-L1) was examined using Western blot analysis, RT-qPCR assay, and immunohistochemistry. The protein-protein interaction between ITGA2 and STAT3 was detected via co-immunoprecipitation.Results: Our study showed that ITGA2 was markedly overexpressed in several malignant tumor cells and clinical tissues. Blocking ITGA2 inhibited the proliferation and invasion ability of cancer cells significantly, whereas overexpressed ITGA2 increased the degree of those processes considerably. Additionally, the RNA-seq assay indicated that ITGA2 transcriptionally regulated the expression of PD-L1 in pancreatic cancer. We also demonstrated that ITGA2 interacted with STAT3 and up-regulated the phosphorylation of STAT3; this interaction might involve the mechanism of ITGA2 inducing PD-L1 expression in cancer cells. Our results suggest that ITGA2 plays a critical role in cancer cell progression and the regulation of PD-L1 by activating the STAT3 pathway.Conclusions: We identified a novel mechanism by which ITGA2 plays a critical role in modulating cancer immune response by transcriptionally increasing the expression of PD-L1 in cancer cells. Thus, targeting ITGA2 is an effective method to enhance the efficacy of checkpoint immunotherapy against cancer.
- 9 December 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
Open AccessOverexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway
Background: Recent studies have reported that Integrin alpha 2 (ITGA2) plays an essential role in tumor cell proliferation, invasion, metastasis, and angiogenesis. An abnormally expressed ITGA2 correlates with unfavorable prognoses in multiple types of cancer. However, the specific mechanism of how ITGA2 contributes to tumorigenesis remains unclear.Methods: The GEPIA web tool was used to find the clinical relevance of ITGA2 in cancer, and this significance was verified using Western blotting analysis of paired patient tissues and immunohistochemistry of the pancreatic cancer tissue. Functional assays, such as the MTS assay, colony formation assay, and transwell assay, were used to determine the biological role of ITGA2 in human cancer. The relationship between ITGA2 and programmed death-ligand 1 (PD-L1) was examined using Western blot analysis, RT-qPCR assay, and immunohistochemistry. The protein-protein interaction between ITGA2 and STAT3 was detected via co-immunoprecipitation.Results: Our study showed that ITGA2 was markedly overexpressed in several malignant tumor cells and clinical tissues. Blocking ITGA2 inhibited the proliferation and invasion ability of cancer cells significantly, whereas overexpressed ITGA2 increased the degree of those processes considerably. Additionally, the RNA-seq assay indicated that ITGA2 transcriptionally regulated the expression of PD-L1 in pancreatic cancer. We also demonstrated that ITGA2 interacted with STAT3 and up-regulated the phosphorylation of STAT3; this interaction might involve the mechanism of ITGA2 inducing PD-L1 expression in cancer cells. Our results suggest that ITGA2 plays a critical role in cancer cell progression and the regulation of PD-L1 by activating the STAT3 pathway.Conclusions: We identified a novel mechanism by which ITGA2 plays a critical role in modulating cancer immune response by transcriptionally increasing the expression of PD-L1 in cancer cells. Thus, targeting ITGA2 is an effective method to enhance the efficacy of checkpoint immunotherapy against cancer.
- Open Access
- 24 April 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 59
Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis
The latest 8th edition of the AJCC staging system emphasizes the importance of tumor size however, the clinical significance of the combination of tumor location with tumor size remains unknown. We conducted this study to investigate the prognostic role of tumor location in T1 resectable pancreatic ductal adenocarcinoma (PDAC). Resectable PDAC patients from Surveillance, Epidemiology, and End Results (SEER) database (2004–2014) were selected for the propensity score matching analysis. We used matched cohort to analyze the relationship between clinicopathologic features and survival of patients. Eight thousand, four hundred nine patients were included in the propensity score matching analysis and 4571 patients were selected for final analysis. In T1 patients, the patients with pancreatic head tumor had worse prognosis compared to the patients with body/tail tumors. Multivariate analysis result showed that pancreatic body/tail location was an independent indicator for better chances of survival in T1 PDAC patients (hazard ratio, 0.69; 95%CI, 0.52–0.93; P = 0.01). The modified staging system was more efficient than the AJCC 8th staging system. Modified staging system exhibited a good assessment of the survival rate. The tumor location is a good prognostic indicator for T1 resectable PDAC patients. Modification of T1 subgroup according to tumor location exhibited favorable survival prediction effects.
- 24 April 2019
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 59
Open AccessTumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis
The latest 8th edition of the AJCC staging system emphasizes the importance of tumor size however, the clinical significance of the combination of tumor location with tumor size remains unknown. We conducted this study to investigate the prognostic role of tumor location in T1 resectable pancreatic ductal adenocarcinoma (PDAC). Resectable PDAC patients from Surveillance, Epidemiology, and End Results (SEER) database (2004–2014) were selected for the propensity score matching analysis. We used matched cohort to analyze the relationship between clinicopathologic features and survival of patients. Eight thousand, four hundred nine patients were included in the propensity score matching analysis and 4571 patients were selected for final analysis. In T1 patients, the patients with pancreatic head tumor had worse prognosis compared to the patients with body/tail tumors. Multivariate analysis result showed that pancreatic body/tail location was an independent indicator for better chances of survival in T1 PDAC patients (hazard ratio, 0.69; 95%CI, 0.52–0.93; P = 0.01). The modified staging system was more efficient than the AJCC 8th staging system. Modified staging system exhibited a good assessment of the survival rate. The tumor location is a good prognostic indicator for T1 resectable PDAC patients. Modification of T1 subgroup according to tumor location exhibited favorable survival prediction effects.